Cardiawave appoints Olivier Pierron as its Chief Executive Officer
April 16 2024 - 7:24AM
Business Wire
Cardiawave SA, a French Medtech company that has developed an
innovative Non-Invasive Ultrasound Therapy (NIUT) device for the
treatment of severe symptomatic calcific aortic stenosis, is
delighted to announce the appointment of Olivier Pierron as its new
Chief Executive Officer. With more than 25 years of experience in
cardiovascular therapies and a passion for innovation, Olivier
Pierron brings to Cardiawave invaluable expertise in the
development and international commercialization of new medical
technologies at a crucial time in the company’s growth, following
the announcement of positive clinical trial results.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240416024431/en/
Olivier Pierron, CEO Cardiawave (Photo:
Cardiawave)
Before joining Cardiawave, Olivier Pierron held executive roles
at some well-known companies in the sector, showing his
capabilities as a manager and innovator in organizations at various
stages of maturity. His international experience, combined with his
involvement in development, acquisition and IPO transactions, makes
him a sound strategic choice to lead Cardiawave towards new
horizons.
Olivier Pierron, Cardiawave’s new CEO, said: “The
approach developed by Cardiawave is unique and complements the
existing range of cardiology treatments. Being entirely
non-invasive, it expands the treatment options of patients
suffering from severe symptomatic aortic valve stenosis. I am very
honored to be joining this visionary team and to be working with
them to bring this disruptive solution to market, in order to treat
the largest number of people as quickly as possible. Cardiawave’s
technology represents a major step forward, one that is
acknowledged by the international medical community, and our
clinical results are very promising. I am determined to make this
innovation a success in our various markets.”
As CEO, Olivier Pierron will take on several exciting challenges
such as deploying Valvosoft® — Cardiawave’s innovative non-invasive
ultrasound therapy for the treatment of severe symptomatic calcific
aortic stenosis — in the European market, starting clinical trials
in the United States under premarket approval, strengthening
strategic partnerships to bolster Cardiawave’s international
footprint, and leading its Series B funding in order to accelerate
its development. Cardiawave has recently reached some key
milestones, such as filing its CE Mark application and completing
the enrollment of 60 patients in its Valvosoft® Pivotal Study,
taking the total number of severe symptomatic calcific aortic
stenosis patients being treated to 100, across 12 research centers
in four European countries. The six-month results of FIH studies
have been published in prestigious scientific journal The Lancet,
strengthening Cardiawave’s position as a leading innovator in the
field of cardiology. Cardiawave is one of the companies supported
by the French Tech Health 20 program, has been a member of La
French Care healthcare industry association since 2023, and has
been a member of the MEDICEN technology cluster, Medtech In France
and France Biotech since 2024.
About CARDIAWAVE www.cardiawave.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240416024431/en/
Cardiawave Olivier Pierron – Directeur Général
cw-ceo@cardiawave.com +33 (0)6 43 95 04 00
Press Stéphanie Lentini slentini@gmail.com +33 (0)7 62 62
51 21